↑ 薬物リストへ　← 戻る

Belantamab mafodotin    (DrugBank: Belantamab mafodotin)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
28全身性アミロイドーシス1

28. 全身性アミロイドーシス　［臨床試験数：212，薬物数：234（DrugBank：72），標的遺伝子数：54，標的パスウェイ数：170］
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 212 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04617925
(ClinicalTrials.gov)		December 202020/10/2020A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL AmyloidosisA Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL AmyloidosisAL AmyloidosisDrug: Belantamab mafodotinEuropean Myeloma NetworkGlaxoSmithKlineNot yet recruiting18 YearsN/AAll35Phase 2Greece